Published in final edited form as:

Cancer Immunol Immunother. 2010 November ; 59(11): 1739–1744. doi:10.1007/s00262-010-0896-z.

ALLOGENEIC NATURAL KILLER CELLS FOR REFRACTORY LYMPHOMA

Veronika Bachanova, MD, Linda J. Burns, MD, David H. McKenna, MD, Julie Curtsinger, PhD, Angela Panoskaltsis-Mortari, MD PhD, Bruce R. Lindgren, MS, Sarah Cooley, MD, Daniel Weisdorf, MD, and Jeffrey S. Miller, MD

Blood and Marrow, Transplant Program, University of Minnesota, Minneapolis, MN 55455

Abstract

We reported that IL-2 activated autologous NK cells can induce, but not maintain durable remissions in lymphoma patients. We hypothesized that allogeneic NK cells may overcome class I MHC-mediated inhibition of NK cell killing. In a pilot study we evaluated infusion of haploidentical donor NK cells for anti-tumor efficacy. Six patients with advanced B-cell non-Hodgkin lymphoma (NHL) received rituximab, cyclophosphamide, and fludarabine as immunosuppression to permit homeostatic NK cell expansion, followed by CD3-depleted NK cell enriched cell products followed by subcutaneous IL-2 administration (10×10^6 units every other day $\times$ 6 doses). At 2 months, four patients showed an objective clinical response. We observed early donor cell persistence in 2 patients (blood and in tumor-bearing node), but this was not detectable beyond 7 days. All patients demonstrated substantial increases in host regulatory T cells (Treg) after NK cell and IL-2 therapy (180 ± 80 cells/ μ l vs baseline: 58 ± 24 cells/ μ l, $p=0.04$) which may have limited donor cell expansion in vivo. These findings suggest safety and feasibility of allogeneic NK cell therapy in patients with lymphoma; however host Treg and inadequate immunodepletion may contribute to a hostile milieu for NK cell survival and expansion. Cell therapy trials should incorporate novel strategies to limit Treg expansion.

Keywords

allogeneic NK cells; adoptive cell therapy; lymphoma

Introduction

The success of allogeneic hematopoietic cell transplantation (HCT) in patients with lymphoma suggests that a potent graft versus lymphoma (GVL) effect exerts protection from relapse [1] from donor derived T-lymphocytes and NK cells [2-5]. In humans, NK cell killing is partially regulated by inhibitory killer immunoglobulin receptors (KIR) that limit autologous NK cells-induced tumor lysis by engagement of “self” major histocompatibility complex (MHC) class I alleles [6, 7]. Donor NK cell therapy has been explored for acute

Address for Correspondence: Veronika Bachanova, MD, Blood and Marrow Transplant Program, University of Minnesota, Mayo Mail Code 480; 420 Delaware Street SE, Minneapolis, MN 55455, bach0173@umn.edu; Phone: 612-624-5620; Fax: 612-625-6919.

The authors declare they have no conflict of interest.

myelogenous leukemia with promising results [8, 9] but there is little data on its activity in lymphoma.

After activation, NK cells acquire the capacity to lyse a broad array of fresh and cultured tumor targets not normally sensitive to NK lysis including lymphoma cell lines. High doses of IL-2 are synergistic with the monoclonal antibody rituximab against rituximab resistant cell lines. This suggests that IL-2 provides a strong stimulus for effective NK mediated antibody-dependent cellular cytotoxicity (ADCC) [10-13]. Several studies have supported a role for IL-2 in the therapy and remission maintenance of NHL, however clinical efficacy has been limited [14-16]. We hypothesized that haploidentical donor NK cells activated by IL-2 and targeted by rituximab would provoke an anti-tumor response in patients with refractory B cell NHL.

Methods

Patients and donors

Patients with relapsed or primary refractory CD20⁺ NHL with adequate organ function who had failed at least 2 salvage therapies were eligible. The protocol and consent procedures were approved by the University of Minnesota institutional review board. Non-mobilized donor peripheral blood mononuclear cells (PBMC) were collected using a Fenwal CS-3000® Plus blood cell separator (#4R4538) with a granulocyte separation chamber and small volume collection chamber (SVCC) (Fenwal Division, Baxter Healthcare, Deerfield, IL).

Preparation of the NK cell product

The apheresis product was T cell- (CD3⁻) depleted using the Miltenyi Biotec CliniMACS® Cell Selection System and CD3 MicroBeads and reagent (Miltenyi Biotec, Auburn, CA) and cultured in serum-free media (X-VIVO 15, Cambrex BioScience, Walkersville, MD) supplemented with 10% human AB serum and 1000 U/mL IL-2 (Chiron Corporation, Emeryville, CA) [17]. Following 8-16 hours incubation, cells were washed twice with a 5% human serum albumin. An aliquot of the cell product was analyzed by flow cytometry to determine the number of T, B and NK cells (using FITC, APC, PE and perCP conjugated antibodies against CD3, CD56, CD19, KIR, NKG2A, NKG2D, CD16, CD69 [BD PharMingen, San Diego, CA]) and tested in a 4-hour Cr-release cytotoxicity assay against K562 cell line pre and post IL-2 incubation [18].

Patients received fludarabine 25 mg/m²/day intravenously (IV) daily (days -6 through -2) and cyclophosphamide 60 mg/kg/days IV day -6 to induce immunosuppression and lymphodepletion required to facilitate homeostatic expansion of allogeneic donor NK cells. Rituximab 375 mg/m² IV was administered on day -8 and then weekly for 3 more doses (days -1, +6, +15) to enhance ADCC. Cell products were administered by intravenous infusion on day 0 followed by subcutaneous IL-2 10 × 10⁶ units starting 4 hours after NK cell infusion and given every other day × 6 doses to facilitate NK cell survival and expansion in vivo. Patients' lymphoma was re-staged at day 28, month 2 and 3 by PET/CT and responses determined according to the IWG 2007 criteria for NHL. Patients in complete

remission had a bone marrow biopsy performed at 2 months. We monitored donor cell persistence by short tandem repeats analysis (STR) of whole peripheral blood (PB) at day 7, 14 and of fine needle aspirates from enlarged lymph nodes obtained between days 8-14. Toxicity and adverse events were classified according to National Cancer Institute Common Terminology Criteria for Adverse Events V 3.0 (CTCAE).

Phenotyping, cytotoxicity, ELISA

Patients' blood was analyzed by flow cytometry pre-chemotherapy, day 0, +7, +14 and +28 with multicolor fluorescent control or specific antibodies directed at CD45, CD56, CD3, CD4, CD25, CD19, CD25, CD127, and Foxp3 (BP PharMingen, San Diego, CA). The frequency of regulatory T cells were analyzed pre-chemotherapy and on day 0 and 14. Plasma IL-15, IL-7, tumor necrosis factor receptor 1 (TNFR1) and IL-10 concentrations were determined by commercial enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN).

Statistical analysis

The prospectively established primary endpoint of this study was to achieve donor NK cell expansion to an absolute level of >100 cells/ μ L at day 14 after NK cell infusion. Cell frequencies were summarized using descriptive statistics. Statistical analysis was performed using Graphpad Prism software (ElCamino, CA) using a paired Student t test. A P value <0.05 was considered statistically significant.

Results

Patient, NK cell product characteristics and clinical outcomes

Six patients with advanced NHL were enrolled. All patients were resistant to rituximab-containing salvage chemotherapy regimens and three patients were refractory to fludarabine. They were ineligible for autologous or allogeneic HCT due to progressive disease. Three out of 6 haploidentical donors-recipient pairs were KIR ligand (HLA) mismatched in the GvH direction (Table 1).

The final NK cell product contained $43 \pm 11\%$ NK cells yielding a dose of $21 \pm 19 \times 10^6$ NK cells/kg. T-cell depletion was efficient with only $0.16 \pm 0.12\%$ contaminating T cells (Figure 1a). The activated NK cell product expressed high levels of FcR γ III CD16 ($85 \pm 6\%$), NKG2D receptors for stress-induced ligands ($40 \pm 5.4\%$) and CD69 ($40 \pm 24\%$) reflective of their pre-infusion activation. The expression of KIR and NKG2A was $80 \pm 2\%$ and $39 \pm 1.8\%$, respectively. Ex-vivo exposure to IL-2 had no impact on these levels. Following ex-vivo IL-2 incubation NK cells were highly cytotoxic against K562 targets (Figure 1b) and expressed 2-fold higher levels of the adhesion molecule CXCR4 ($37 \pm 9\%$ vs $17.6 \pm 3\%$; $P=0.03$).

The high-dose chemotherapy and NK cell infusion did not induce unexpected toxicity. Five of 6 patients completed all prescribed IL-2 doses. No patient developed prolonged marrow aplasia or GVHD. Non-hematologic toxicities were NCI CTCAE grade 1-3 rigors and fevers with the NK cell infusion (4 patients), skin redness/swelling at IL-2 injection site (4

patients), fatigue (3 patients), sepsis (1 patient), hypertension (1 patient), bigeminy related to electrolyte disturbance (1 patient) and tumor-induced airway obstruction (1 patient). In one patient IL-2 was stopped after the 4th dose due to dyspnea with pulmonary infiltrates. The patients' condition rapidly improved with antifungal therapy although no fungal infection was documented. We observed grade 3 neutropenia and thrombocytopenia in all patients. Mean time to neutrophil and platelet recovery was 12 (range 10-16 days) and 14 days (range 3-38 days), respectively. One patient had delayed hematologic recovery associated with human herpes virus-6 infection, which responded to treatment with foscarnet. This patient was not evaluable for PB cell analysis due to prolonged lymphopenia until day 30.

Clinical outcomes are summarized in Table 1. Four patients achieved objective remissions (2 complete remissions, 2 partial remissions) on day 28 which were maintained at the 2 month post therapy evaluation. Two patients (#1 and #2) with complete resolution of lymphoma on PET/CT also cleared their bone marrow of lymphoma at 2 months. Three responding patients underwent allogeneic donor HCT at 116, 70 and 62 days post NK cell therapy with no evidence of disease progression at the time of transplant. The PR in the 4th responding patient lasted 123 days.

Lack of donor NK cell persistence in blood and tissues

We hypothesized that transient donor NK cell in vivo expansion and persistence is a prerequisite to clinical efficacy. One patient demonstrated PB donor cell expansion (43% circulating donor cells) at day 7 following NK cell infusion, which were replaced by all host cells at later time-points. At day 14 and 28, none of the patients had detectable donor cells. NK cells did not significantly change after IL-2 therapy (percentage of lymphocytes and absolute NK cells [mean (range) pre-chemotherapy vs day 14: $31 \pm 12\%$ vs day 28 $\pm 11\%$; 94 NK cells/ μ l (range 0-129) vs 137 NK cells/ μ l (range 0-520); $p=NS$).

To investigate the possibility of NK cell trafficking to affected lymph nodes, we performed fine needle aspiration of palpable tumor in three patients, but obtained a sufficient quantity of cells from only one patient. This needle aspirate (at day 14 after NK infusion) showed 2.1% donor cells by STR and 3% of lymphocytes were NK cells. Given the absence of donor NK cells in the blood of this patient, the future study of donor NK cells homing to tumor-bearing lymph nodes is warranted.

Host regulatory T cells proliferate following IL-2 therapy

Pre-infusion chemotherapy led to lymphodepletion and an endogenous release of IL-7 and IL-15 as shown previously [8]. However lymphodepletion was incomplete and transient as demonstrated by persistence of recipient T cells immediately before NK cell infusion (Figure 1d) and rapid recipient T lymphocyte recovery at day 14 with a mean absolute lymphocyte count of 695 ± 83 cells/ μ l (mean: $63 \pm 25\%$ T lymphocytes; $28 \pm 11\%$ NK cells). To understand this prompt immune reconstitution after high dose therapy, we examined the phenotype of T cells for the presence of the regulatory T cell (Treg) subset. We observed a 3- fold increase of $CD4^+CD127^{-/low}CD25^+$ cells following 14 days of IL-2 therapy compared to baseline ($31.1 \pm 13\%$ vs $9.82 \pm 4\%$; $n=5$, $P=0.003$) which lead to an absolute Treg cell increase ([mean $\pm$ SEM] 180 ± 80 cells/ μ l vs 58 ± 24 cells/ μ l; $P=0.04$; Figure 1c).

The Treg expressed high levels of Foxp3 (Figure 1d). Phenotypic and functional characteristics of these cells suggest modest immunosuppressive activity (not shown). Expansion of Tregs correlated with 2-fold increase in plasma levels of TNFR1 and IL-10 at day 14 compared to pre-NK infusion levels (Figure 1c). In contrast, no differences in absolute cytotoxic T cells (CD3⁺CD4⁻) were observed after therapy compared to pre-chemotherapy (Figure 1c). These findings suggest that inadequate lymphodepletion followed by IL-2 administration can permit enhanced host Tregs. By active suppression, secretion of inhibitory cytokines or possibly by competition for exogenous IL-2 the Tregs may have interfered with donor NK cell proliferation and activation. Since the primary endpoint of NK cell expansion was not met, we adhered to prospectively designed stopping rules and closed the trial after enrolling 6 patients.

Discussion

In this pilot trial we demonstrated feasibility and safety of haploidentical NK cells infusions in NHL patients. Our findings suggest that in vitro IL-2 activation improves donor NK cells cytotoxicity and can impact on homing to bone marrow by increased expression of CXCR4 on NK cells. We observed objective clinical responses in 4 patients but without sustained donor NK cell expansion in peripheral blood. Therefore, the objective clinical responses observed cannot be directly associated with NK cell therapy. NK cell responses cannot be separated from the pre-infusion chemo-immunotherapy and IL-2 despite their clinical tumor progression following similar chemotherapy agents used previously. It is also not known what level of NK cell expansion will result in clinical efficacy. In fact, one study using adoptive T cell therapy reported major tumor responses without evidence of sustained donor chimerism so the threshold may be very low [19].

Importantly, our observations led to the identification of host factors that may have interfered with donor NK cell expansion, particularly host Treg proliferation. Transient lymphodepletion following high-dose chemotherapy spared regulatory T cells and exogenously administered IL-2 allowed their proliferation. Although immune properties of IL-2 induced Tregs are not well understood, functional testing and cytokine profiles suggest immunosuppressive potential that could interfere with donor NK cells survival, expansion and activation [20, 21]. Our findings are particularly relevant in the context of recent animal observations, which demonstrated that endogenous Treg interfered with NK cell proliferation and function and combination therapy using IL-2 and anti-CD25 results in augmented NK cell-mediated antitumor responses [22]. In addition, depletion of Tregs by IL-2 diphtheria toxin facilitated expansion of transferred cytotoxic T-lymphocytes and significantly enhanced leukemia killing and prolonged survival of animals with AML when compared to T cell infusion alone [23].

The conditions required for survival and expansion of adoptively transferred lymphocytes in humans are not known and remain an area of active clinical research. Development of optimal chemotherapy to prolong survival and homing of infused NK cells are beginning to be understood. Our results suggest that future adoptive donor cell transfer chemotherapies may benefit from specific agents to eliminate or prevent Treg expansion.

Acknowledgments

The clinical trial was supported in part by a gift from the patient advocate group, CLL Topics, Inc. We would like to thank our dedicated research staff, nurse practitioner Megan Whitmore, research nurses Dixie Lewis and Roby Nicklow and clinical trial office staff, Jill Aughey, for their outstanding support and invaluable contributions in conducting the trial. We want to thank Michael Franklin and Carol Taubert for editorial assistance. We want to acknowledge the University of Minnesota Masonic Cancer Center Translational Therapy Core for their excellent assistance.

REFERENCES

1. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B. Graft-versus-leukemia reactions after bone marrow transplantation. *Blood*. 1990; 75:555–562. [PubMed: 2297567]
2. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. *Science*. 2002; 295:2097–2100. [PubMed: 11896281]
3. Novitzky N, Thomas V. Allogeneic stem cell transplantation with T cell-depleted grafts for lymphoproliferative malignancies. *Biol Blood Marrow Transplant*. 2007; 13:107–115. [PubMed: 17222759]
4. Chandon Y, Roosnek E, Mermillod B, Waelchli L, Helg C, Chapuis B. Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study. *Biol Blood Marrow Transplant*. 2006; 12:102–110. [PubMed: 16399574]
5. Perales MA, Jenq R, Goldberg JD, Wilton AS, Lee SS, Castro-Malaspina HR, Hsu K, Papadopoulos EB, van den Brink MR, Boulad F, Kernan NA, Small TN, Wolden S, Collins NH, Chiu M, Heller G, O'Reilly RJ, Kewalramani T, Young JW, Jakubowski AA. Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. *Bone Marrow Transplant*. 2010
6. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, Vitale M, Bottino C, Moretta L, Moretta A, Long EO. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. *Immunity*. 1995; 2:439–449. [PubMed: 7749980]
7. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. *Science*. 1995; 268:405–408. [PubMed: 7716543]
8. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. *Blood*. 2005; 105:3051–3057. [PubMed: 15632206]
9. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W. NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. *J Clin Oncol*. 2010
10. Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma. *J Immunother*. 2007; 30:64–74. [PubMed: 17198084]
11. Hooijberg E, Sein JJ, van den Berk PC, Hart AA, van der Valk MA, Kast WM, Melief CJ, Hekman A. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. *Cancer Res*. 1995; 55:2627–2634. [PubMed: 7540106]
12. Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodegua L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and

- interleukin-2: a preclinical and phase I study. *Clin Cancer Res.* 2004; 10:6101–6110. [PubMed: 15447996]
13. Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J Jr, Burns LJ. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. *Biol Blood Marrow Transplant.* 1997; 3:34–44. [PubMed: 9209739]
 14. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. *N Engl J Med.* 1987; 316:889–897. [PubMed: 3493432]
 15. Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. *Clin Cancer Res.* 2006; 12:7046–7053. [PubMed: 17145827]
 16. Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, Burger SR, Panoskaltis-Mortari A, Keever-Taylor CA, Zhang MJ, Miller JS. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. *Bone Marrow Transplant.* 2003; 32:177–186. [PubMed: 12838283]
 17. McKenna DH, Kadidlo DM, Miller JS, Orchard PJ, Wagner JE, McCullough J. The Minnesota Molecular and Cellular Therapeutics Facility: a state-of-the-art biotherapeutics engineering laboratory. *Transfus Med Rev.* 2005; 19:217–228. [PubMed: 16010652]
 18. Miller JS, Oelkers S, Verfaillie C, McGlave P. Role of monocytes in the expansion of human activated natural killer cells. *Blood.* 1992; 80:2221–2229. [PubMed: 1421393]
 19. Colvin GA, Berz D, Ramanathan M, Winer ES, Fast L, Elfenbein GJ, Quesenberry PJ. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. *Biol Blood Marrow Transplant.* 2009; 15:421–431. [PubMed: 19285629]
 20. Barao I, Hanash AM, Hallett W, Welniak LA, Sun K, Redelman D, Blazar BR, Levy RB, Murphy WJ. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. *Proc Natl Acad Sci U S A.* 2006; 103:5460–5465. [PubMed: 16567639]
 21. Zimmer J, Andres E, Hentges F. NK cells and Treg cells: a fascinating dance cheek to cheek. *Eur J Immunol.* 2008; 38:2942–2945. [PubMed: 18979513]
 22. Hallett WH, Ames E, Alvarez M, Barao I, Taylor PA, Blazar BR, Murphy WJ. Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses. *Biol Blood Marrow Transplant.* 2008; 14:1088–1099. [PubMed: 18804038]
 23. Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH, Levine BL, Riddle M, June CH, Vallera DA, Weigel BJ, Blazar BR. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. *Blood.* 2009; 114:3793–3802. [PubMed: 19724059]

FIGURE 1.

a. Allogeneic NK cell products and ex-vivo expansion. Total nucleated cell (TNC), CD56⁺/CD3⁻ NK cell and CD3⁺ T cell frequencies (mean ± SEM) in 6 apheresis products, after CD3 depletion and overnight activation with 1000 IU/ml IL-2. b. CD3 depleted clinical products (n=6) were tested in Cr₅₁ release cytotoxic assay against K562 targets before and after ex-vivo incubation with 1000 IU/ml IL-2 at E:T ratio as shown (* p<0.05). c. Regulatory T cells increase after NK cell and IL-2 therapy. Patients with refractory lymphoma received pre-infusion chemotherapy, haploidentical donor NK cell infusion and IL-2 × 6 doses. Absolute numbers of regulatory T cells, cytotoxic CD3⁺CD4⁻ lymphocytes, serum levels of tumor necrosis factor receptor 1 and IL-10 are compared at baseline and at day 14. Mean cell frequencies ± SEM of 5 evaluable patients are shown. (* p<0.05) d. Flow cytometric detection of T lymphocytes subsets and Treg in peripheral blood at baseline, day 0 (prior to allogeneic NK cells infusion) and day 14 (following IL-2 therapy) are compared. Representative plot from patient #6 is shown.

TABLE 1

Clinical and disease characteristics.

Pt	Diagnosis	Age	Prior regimens	Stage	BM+	Flu R	Rit R	Response	KIR-L MM	Time to next therapy	Subsequent therapy	Outcome
1	Marginal zone lymphoma	48	5	IVB	yes	yes	yes	CR	yes Bw4	116 days	MRD HCT	Alive in CR 6+ months
2	Follicular lymphoma	49	4	IVB	yes	yes	yes	CR	yes C2	70 days	MRD HCT	Alive in CR 5+ months
3	Transformed lymphoma	57	5	IVB	yes	yes	yes	PR	No	62 days	DUCB HCT	Alive, relapse at 6 months
4	DLBCL	76	6+XRT	IEA	no	N	yes	PR	yes C1	123 days	Chemotherapy	Alive, relapse at 6 months
5	DLBCL	48	3	IVB	no	N	yes	NR	no	45 days	Clinical trial	Dead
6	Transformed lymphoma	35	3+XRT	IIIEA	no	N	yes	NR	no	-	Palliative care	Dead

Abbreviations: DLBCL, diffuse large B cell lymphoma; N, not received; BM, bone marrow; flu, fludarabine; rit, rituximab; XRT, radiation therapy; CR, complete remission; PR, partial remission; NR, no response; Flu R, Fludarabine refractory; Rit R, rituximab refractory; MRD, matched related donor; DUCB, double umbilical cord blood; HCT, hematopoietic cell transplantation; KIR-L MM, Killer immunoglobulin receptor-ligand (Class I HLA mismatch) in graft versus host direction.